undamentalytics Newsletter
Sign in

Tarsus Pharmaceuticals, Inc. revenue

Tarsus Pharmaceuticals, Inc.'s revenue was $451m in fiscal 2025, up 146.7% on the year before. Since fiscal 2021 ($57.0m) it has grown at a compound 67.7% a year. Over the last twelve months it was $606m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0572617183451606
Growth on the year before——−54.7%−32.4%+948.6%+146.7%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $451M 100.0% ▲ 150.7%
License and Collaboration $0 0.0% ▼ 100.0%

From Tarsus Pharmaceuticals, Inc.'s 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Tarsus Pharmaceuticals, Inc. $606m 105.2% 264.7%
Mirum Pharmaceuticals, Inc. $618m 44.0% 74.8%
Arrowhead Pharmaceuticals, Inc. $669m 16.8% 37.7%
Hutchmed (china) Ltd $549m -13.0% —
Nurix Therapeutics, Inc. $702m 738.8% 117.1%
Ultragenyx Pharmaceutical Inc. $717m 17.5% 21.2%

Compare with peers

Head to head: MIRM vs TARSARWR vs TARSHCM vs TARS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tarsus Pharmaceuticals, Inc.